Daniel S. Och’s OZ Management is among the investment management firms required to disclose their long equity positions once per quarter.
Keep Reading →
August 22 - Hedge Funds, News - Comments
Legendary corporate raider Carl Icahn recently filed his second quarter Form 13F with the SEC.
Keep Reading →
August 22 - Hedge Funds, News - Comments
In its latest 13F filing, GLG Partners, managed by Noam Gottesman, disclosed equity position as held at the end of June, 2014.
Keep Reading →
August 15 - Hedge Funds, News - Comments
Harvard Management Company Chief Executive Officer, Jane Mendillo, shared her investment philosophy on CNBC, during an interactive program which was held on the sidelines of...
Keep Reading →
July 17 - Hedge Funds, News - Comments
Clint Carlson’s fund Carlson Capital has disclosed in a recent filing with the SEC a letter sent to the Special Committee of the Board of Directors of SWK Holdings Corp (OTCMKTS...
Keep Reading →
June 23 - Hedge Funds, News - Comments
Deepak Gulati is the former head of global equity proprietary trading at JPMorgan Chase & Co.
Keep Reading →
May 28 - Hedge Funds, News - Comments
Mario Gabelli's GAMCO Investors is one of the most prominent funds in the investment universe, which is why we consider that its activity should be followed closely, especially...
Keep Reading →
May 6 - Hedge Funds, News - Comments
Since 1983, Depakote ER has been a good source of revenue for drug manufacturers. The drug is mainly used in the treatment of bipolar disorder, migraines, and seizures.
Keep Reading →
September 13 - News - Comments
Activist investor Carl Icahn said he bought more shares of Apple Inc. (NASDAQ:AAPL) on Wednesday as the company's stock price slid.
Keep Reading →
September 11 - Hedge Funds - Comments
Orphan drug status, which is given to drugs meant for the treatment of rare diseases, offers drug developers a path to faster approval and enhanced market exclusivity.
Keep Reading →
September 6 - News - Comments
Pharmaceutical firms spend a lot of money to influence physicians to prescribe their products.
Keep Reading →
September 5 - News - Comments
In the 21st century investor’s toolkit, there are a multitude of metrics investors can use to track Mr. Market.
Keep Reading →
September 5 - News - Comments
In today’s marketplace, there are many metrics market participants can use to track publicly traded companies.
Keep Reading →
August 28 - News - Comments
Alkermes Plc (NASDAQ:ALKS) is primarily known for its schizophrenia and multiple sclerosis drug treatments.
Keep Reading →
August 26 - News - Comments
In the eyes of many of your fellow readers, hedge funds are seen as useless, old financial vehicles of an era lost to time.
Keep Reading →
August 26 - News - Comments
If you were to ask many investors, hedge funds are seen as delayed, old financial tools of an era lost to time.
Keep Reading →
August 25 - News - Comments
Editor’s Note: A previous version of this post incorrectly stated that Eli Lilly’s experimental drug solanezumab is a BACE inhibitor.
Keep Reading →
August 23 - News - Comments
For years, satirical late-night TV host Stephen Colbert has been running a series on his show called "Better Know a District," which highlights one of the 435 U.S.
Keep Reading →
August 20 - News - Comments
With the SPDR S&P Biotech Index up 34% over the trailing-12-month period, it's evident that investment dollars are willingly flowing into the biotech sector.
Keep Reading →
August 19 - News - Comments
Second-quarter earnings season was a bit of a bust. Although earnings remain at an all-time high, the pace of earnings growth continues to look weak.
Keep Reading →
August 14 - News - Comments
In June this year, a drug candidate from Cubist Pharmaceuticals Inc (NASDAQ:CBST) received fast track status from the FDA.
Keep Reading →
August 5 - News - Comments
With the SPDR S&P Biotech Index up 29% over the trailing-12-month period, it's evident that investment dollars are willingly flowing into the biotech sector.
Keep Reading →
July 29 - News - Comments
With taxes having risen for most people at the beginning of 2013, ordinary Americans are increasingly angry about the steps that many well-known U.S.
Keep Reading →
July 26 - News - Comments
Investors love stocks that consistently beat the Street without getting ahead of their fundamentals and risking a meltdown.
Keep Reading →
July 10 - News - Comments
The news flow from biotech companies might slow down during the summer, but it won't stop.
Keep Reading →
July 1 - News - Comments
The biotechnology sector is rapidly evolving, and what was a near-guarantee of success of getting a drug approved by the Food and Drug Administration 10 years ago is no longer...
Keep Reading →
June 3 - News - Comments
Forest Laboratories, Inc. (NYSE:FRX) was in 35 hedge funds' portfolio at the end of March.
Keep Reading →
May 28 - News - Comments
Gloom, despair, and agony. Shareholders of at least three health-care stocks experienced one or more of these feelings over the past few days.
Keep Reading →
May 28 - News - Comments
Every Sunday I make it a point to examine a combination of earnings stories or Food and Drug Administration panel reviews or PDUFA decisions in the upcoming week that you can'...
Keep Reading →
May 5 - News - Comments
The biotech sector can occasionally throw a curveball at investors. For Trius Therapeutics, Inc.
Keep Reading →
March 26 - News - Comments
As first-quarter earnings get ready to kick into high gear, I can't help but point out that the majority of earnings reports we've covered over the past year have been better ...
Keep Reading →
January 22 - News - Comments
In the past two weeks, activist investor Carl Icahn has purchased nearly 420,000 shares of Forest Laboratories, Inc. (NYSE:FRX) worth a total of $14.5 million.
Keep Reading →
September 11 - Hedge Funds, Insider Trading - Comments
According to a 13G just filled with the Securities and Exchange Commission (SEC), Steven Mandel’s Lone Pine Capital LLC has now owns 8,645,289 shares of Verisign, Inc.
Keep Reading →
August 28 - Hedge Funds - Comments
T. Boone Pickens, who made his billions on oil, is adding to them on the back of the commodity this year.
Keep Reading →
August 24 - Hedge Funds - Comments
Carl Icahn is pushing a split at truck maker Oshkosh Corp., urging it to spin a unit he’s called a mistake in the past because its value is being obscured.
Keep Reading →
August 10 - Hedge Funds - Comments
BarclayHedge and TrimTabs Investment Research reported today that the hedge fund industry redeemed $4.9 billion (0.3% of assets) in June, compared with inflows of $1.1 billion...
Keep Reading →
August 9 - Hedge Funds - Comments
New York City, embracing an experimental mechanism for financing social services that has excited and worried government reformers around the world, will allow Goldman Sachs to...
Keep Reading →
August 2 - Hedge Funds - Comments
The European arm of the Tudor Group, the US hedge fund founded by Paul Tudor Jones II, paid its staff a bumper $62m last year after a profitable 2011, despite the travails of ...
Keep Reading →
July 26 - Hedge Funds - Comments
I am appealing to you directly because to date my overtures to Howard Solomon have fallen on deaf ears. I am concerned that we are reaching a precipice in this proxy contest...
Keep Reading →
July 12 - Hedge Funds - Comments
Marcus Agius, the chairman of Barclays, resigned on Monday, less than a week after the big British bank agreed to pay $450 million to settle accusations that it had tried to manipulate...
Keep Reading →
July 2 - Hedge Funds - Comments
Philip Falcone’s hedge fund, having taken out a loan earlier this year at an effective annual interest rate of 24 percent, has found a new source of financing: the money-management...
Keep Reading →
June 20 - Hedge Funds - Comments
